HTN
The prevalence of HTN in all patients was high, with 19 of 45 having HTN (42.2%, 95% CI: 22.0-63.6%). In univariate analysis, no variable was significant as a risk factor for HTN. In these 19 HTN patients, one had left ventricular hypertrophy noted on previous echocardiogram. None of the 26 non-HTN patients had LVH on previous echocardiograms. However, these echocardiograms were obtained as part of standard of care prior to initiation of ALL therapy rather than at time of enrollment in this renal outcomes study. Eight of 24 patients were on chronic anti-HTN treatment at some point in time and 2 of these patients were actively taking anti-HTN medications at the time of study enrollment. All patient who received chronic anti-HTN treatment were prescribed the calcium channel blocker amlodipine.
In the 21 patients who completed an ABPM study, 14 had an abnormal result (67%, 95% CI: 43-85%). Of these 21 patients, 13 had normal casual BP values and of this group, 7 (54%) had abnormal ABPM readings, therefore being designated as having abnormal BP by ABPM even though by casual BP readings their BP was normal. On ABPM, one patient with known HTN had well-controlled BP on chronic anti-HTN medication. One patient was noted to have pre-HTN. One patient was noted to have nocturnal HTN. Eleven patients had abnormal nocturnal dipping pattern: 10 patients were non-dippers, with no physiologic decline in sleep BPs, and 1 patient was an extreme dipper, with greater than 20% decline in sleep MAP compared to wake MAP. In univariate analysis, no variable was significant as a risk factor for abnormal ABPM.